Results 121 to 130 of about 3,499 (203)

Abbreviated atovaquone-proguanil prophylaxis regimens in travellers after leaving malaria-endemic areas: A systematic review. [PDF]

Travel Med Infect Dis, 2018
Savelkoel J, Binnendijk KH, Spijker R, van Vugt M, Tan K, Hänscheid T, Schlagenhauf P, Grobusch MP.   +7 more
europepmc   +1 more source

Collapsing glomerulopathy after Plasmodium falciparum infection [PDF]

, 2014
Alphen, A.M. (Adriaan) van, Genderen, P.J.J. (Perry) van, Goemaere, N.N.T. (Natascha), Wolfswinkel, M.E. (Marlies) van   +3 more
core   +2 more sources

Artemether-lumefantrine compared to atovaquone-proguanil as a treatment for uncomplicated Plasmodium falciparum malaria in travelers. [PDF]

Am J Trop Med Hyg, 2015
Grynberg S, Lachish T, Kopel E, Meltzer E, Schwartz E.   +4 more
europepmc   +1 more source

Acute Respiratory Distress Syndrome Caused by \u3cem\u3ePlasmodium falciparum\u3c/em\u3e Infection [PDF]

, 2016
Luedke, Patricia G., Munson, Erik, Timm, William D.   +2 more
core   +1 more source

Dual function of mitochondrial complex III in Plasmodium falciparum. [PDF]

PLoS One
Rell RS, Shukla A, Morrisey JM, Okoye IC, Mather MW, Vaidya AB.   +5 more
europepmc   +1 more source

Atovaquone-Proguanil Remains a Potential Stopgap Therapy for Multidrug-Resistant Plasmodium falciparum in Areas along the Thai-Cambodian Border. [PDF]

Antimicrob Agents Chemother, 2015
Saunders DL, Chaorattanakawee S, Gosi P, Lanteri C, Somethy S, Kuntawunginn W, Ittiverakul M, Chann S, Gregory C, Chuor CM, Prom S, Spring MD, Lon C.   +12 more
europepmc   +1 more source

Accessibility to antimalarials in Spanish hospitals: analysis of a national survey. [PDF]

Malar J
Bretones-Pedrinaci JI, Castro-Vida MA, Urda-Romacho J, Lozano-Serrano AB, Salas-Coronas J.   +4 more
europepmc   +1 more source

Mechanistic perspectives on antimalarial agents: from FDA-approved drugs to next-generation candidates. [PDF]

RSC Adv
Monika, Sharma B, Awasthi SK.
europepmc   +1 more source

Safety profile of Coartem: the evidence base [PDF]

, 2009
Catherine Falade, Christine Manyando, Novartis Drug Regulatory Affairs, M Makanga, M van Vugt, M van Vugt, G Lefèvre, C Falade, C Hatz, S Abdulla, H Bukirwa, G Dorsey, R Gürkov, MR Kamya, A Mårtensson, AO Mohamed, A Yeka, M Mulenga, GO Adjei, CO Falade, B Faye, KA Koram, S Owusu-Agyei, I Sagara, A Sowunmi, CJ Sutherland, I Zongo, I Zongo, CI Fanello, A Ndayiragije, I van den Broek, S Krudsood, JM Stohrer, M Mayxay, A Ratcliff, R Hutagalung, IV van den Broek, S Thapa, EA Mueller, M Makanga, LA Panossian, LG Miller, C Franco-Paredes, NJ White, TME Davis, PN Newton, E Kissinger, M van Vugt, R Hutagalung, MBB McCall, M Cousin, NJ White, R Bakshi, GO Adjei, C Maiteki-Sebuguzi, R McGready, C Manyando   +56 more
core   +1 more source

4-nitrobenzoate inhibits 4-hydroxybenzoate polyprenyltransferase in malaria parasites and enhances atovaquone efficacy. [PDF]

FEBS Lett
Verdaguer IB, Santos MF, Filho MM, Castro GO, Hernández A, Peres MA, Katzin AM, Crispim M.   +7 more
europepmc   +1 more source